Lucid Diagnostics Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds On March 22, 2024, the Company approved the issuance to an investor relations firm it had engaged a three-year option to acquire 100,000 shares of the Company’s common stock, with an exercise price of $1.50 per share. The option vests in two equal installments on May 31, 2024 and August 31, 2024. The offer and sale of the option and the underlying shares of common stock is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act, as a transaction not involving a public offering. Except as set forth above and as previously disclosed in our current reports on Form 8-K filed prior to the date of this Form 10-Q and in the Annual Report, we did not sell any unregistered securities or repurchase any of our securities during the three months ended March 31, 2024. See Part I, Item 2 under the caption “ Liquidity and Capital Resources ” for a description of limitations on the payment of dividends.